Pharma News
09 Nov 2025 to 15 Nov 2025
Nov 15, 2025
Individual apprehended with MD substances valued at Rs 2.5 lakh | Indore News - The Times of India
Indore Crime Branch arrested Sohel Khan for possessing 25.39 grams of MD, a synthetic drug valued at nearly Rs 2.5 lakh. The arrest occurred during routine checks under Navda Panth Bridge, where Khan attempted to evade police. He confessed to buying the drug at lower prices to sell to addicts in Indore for profit, leading to charges under the NDPS Act.
Nov 15, 2025
Nine individuals apprehended in Kadapa district for trafficking in marijuana and illegal prescription medications.
Nine individuals, including notorious rowdy-sheeter Surabhi Mahesh and medical shop owner Sanniti Nagendra Guptha, were arrested in Kadapa for selling ganja and Tapedac 100mg tablets (Tapentadol). The police seized 23.5 kg of ganja and 1,620 Tapedac tablets. The gang reportedly targeted youth for illegal profits. All accused have been sent to judicial remand.
Nov 15, 2025
The Effects of the General Proximity Partnership and STING Agonist Trial on Daiichi Sankyo
General Proximity has partnered with Daiichi Sankyo to utilize its OmniTAC platform for developing new oncology therapies. Daiichi Sankyo has also initiated a first-in-human trial for its STING agonist ADC, DS3610, targeting advanced solid tumors. This collaboration aims to enhance Daiichi Sankyo's oncology portfolio amid rising R&D costs and revenue concentration risks.
Nov 15, 2025
Cardiol Therapeutics has been granted a notice of allowance for its patent application by the US Patent and Trademark Office.
Cardiol Therapeutics Inc. has received a notice of allowance for its US patent application on "cannabidiol-patent-expiration" style="color: #F36C42; font-weight:600";>Cannabidiol Compositions for Use in Treating Heart Conditions." This patent will protect CardiolRx (cannabidiol) and CRD-38 for various cardiac conditions until 2040. The company aims to advance clinical programs for recurrent pericarditis and acute myocarditis, enhancing its market position and IP portfolio.
Nov 15, 2025
CDSCO Intensifies Schedule M Inspections Ahead of December 2025 Deadline
The Central Drugs Standard Control Organisation (CDSCO) is intensifying inspections for small and medium enterprises (SMEs) as the December 31, 2025, deadline for compliance with the Revised Schedule M under the Drugs Rules, 1945, approaches. SMEs are urged to meet the regulatory requirements to avoid penalties.
Nov 15, 2025
Haryana Company Caught Distributing Fake Medications to Ladakh Under Himachal Pharma Branding
Authorities in Himachal Pradesh have arrested a Haryana firm for supplying counterfeit medicines, including Cefixime Tablets IP 200 mg and Amoxicillin Trihydrate Dispersible Tablets IP 250 mg, labeled as products of SVR Healthcare. This scandal highlights significant concerns regarding pharmaceutical fraud and compliance with the Drugs and Cosmetics Act 1940.
Nov 15, 2025
Study Examines the Effects of GLP-1 Medications on Heart and Kidney Health in Veterans with Type 2 Diabetes
A study published in JAMA Network Open by Dr. Catherine Derington compared the safety of GLP-1 receptor agonists—liraglutide, semaglutide, and dulaglutide—among 21,790 veterans with type 2 diabetes. Findings suggest all three drugs have low health risks, though semaglutide showed a higher gallstone risk. Further research is needed to validate these results across diverse populations.
Nov 15, 2025
US Expenditure on High-Value Medications for Rare Diseases in 2022 | AJMC
In 2022, 19 of the top 100 highest-revenue prescription drugs in the US were exclusively approved for rare diseases, generating $45.1 billion in spending, or 7.5% of total prescription drug costs. Notable drugs included lenalidomide (Revlimid) and elexacaftor/tezacaftor/ivacaftor (Trikafta). The findings highlight the need for policy reforms to address high costs associated with these medications.
Nov 14, 2025
New Zealand boxing champion Joseph Parker may face suspension following a positive drug test prior to his highly anticipated match.
Former world heavyweight champion Joseph Parker failed a drug test on October 25, the day before his fight against Fabio Wardley, according to his promoter Queensberry. The Voluntary Anti-Doping Association (VADA) reported an adverse finding, with initial reports suggesting a positive test for cocaine. Parker's future may be jeopardized pending the investigation's outcome.
Nov 14, 2025
Five individuals, including three women and two men, taken into custody following a €2.1 million drug bust - The Irish Times
Five individuals were arrested in Dublin and Wicklow after the Garda National Drugs and Organised Crime Bureau seized €2.1 million worth of cannabis (98kg) and cocaine (2kg). The operation, part of Operation Tara, aims to combat drug trafficking networks. The arrested individuals are being detained under various sections of the Criminal Justice Act. Investigations continue.
Nov 14, 2025
Celebrities expected to be interrogated in ₹252 crore drug investigation | Mumbai News - The Times of India
Mumbai police's anti-narcotics cell plans to record statements from Bollywood celebrities, a rapper, a socialite, and a slain politician's son after alleged drug smuggler Sohail Shaikh claimed he supplied them drugs and attended raves with them. Authorities aim to verify his claims and gather admissible evidence before proceeding, following Shaikh's arrest in a Rs 252-crore drug case.
Nov 14, 2025
FDA's strategy to increase the availability of affordable generic medications may face delays at the patent office - CBS News
The FDA plans to streamline the approval process for biosimilars, potentially reducing costs by up to 90% for drugs like Humira and Keytruda. However, the U.S. Patent Office is complicating matters by restricting patent challenges, hindering market entry for cheaper alternatives. Industry officials express concern that these patent barriers could delay access to affordable medications for patients.
Nov 14, 2025
25 Pharmacies Prohibited in Uttar Pradesh as Part of Anti-Drug Initiative, DrugsControl Media Services
Dr. Roshan Jacob, Secretary & Commissioner of the Food Safety & Drug Administration (FSDA) in Uttar Pradesh, has led a crackdown on illegal drug trade, resulting in the banning of 25 medical stores. This initiative aims to enforce the Drugs and Cosmetics Act and strengthen regulatory compliance in the region.
Nov 14, 2025
Supplier of psychotropic medications apprehended at Moon Medicos in Najafgarh!
Delhi Police Crime Branch has arrested Virendra Singh, a chemist shop owner from Moon Medicos in Najafgarh, for illegally selling psychotropic medicines at prices three times higher than the maximum retail price. The operation dismantled an interstate drug racket.
Nov 14, 2025
Weight loss medications Ozempic, Wegovy, and Mounjaro demonstrate remarkable survival advantages for...
Researchers at UC San Diego found that GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, significantly reduce the five-year mortality rate for colon cancer patients. Only 15.5% of GLP-1 users died within five years, compared to 37.1% of non-users. While promising, further clinical trials are needed to confirm these findings and establish a direct link to cancer survival.
Nov 14, 2025
Merck invests $9.2 billion in Cidara Therapeutics to enhance flu prevention efforts - TradingView
Merck (MRK) will acquire Cidara Therapeutics (CDTX) for approximately $9.2 billion, paying $221.50 per share, a 108.9% premium. This acquisition includes Cidara's experimental flu drug CD388, which aims to provide universal prevention against flu strains. The deal, expected to close in Q1 2026, is part of Merck's strategy to diversify ahead of patent losses for Keytruda.
Nov 14, 2025
Chinese physicians advocate for insurance to include weight-loss medications | The Straits Times
In China, doctors are advocating for national insurance coverage of weight-loss drugs to combat rising obesity rates, which are projected to exceed 65% by 2030. The high cost of treatments, such as Novo Nordisk's Wegovy, poses a barrier for patients. Experts suggest subsidizing GLP-1 drugs to aid those with serious health issues, while competition from generics may lower prices.
Nov 14, 2025
Bristol Myers and Johnson & Johnson's new anticoagulant does not succeed in its initial major trial | BioPharma Dive
Bristol Myers Squibb and Johnson & Johnson have halted a late-stage trial of their experimental anticoagulant, milvexian, after it failed to show superiority over standard treatments in preventing cardiovascular complications post-heart attack. Despite this setback, two other trials for milvexian are ongoing, with potential implications for stroke prevention and atrial fibrillation.
Nov 13, 2025
The GLP-1 breakthrough: Weight loss medications poised to lead the medical field for the next five decades.
At the Dakshin Health Summit, experts highlighted that obesity treatments, particularly GLP-1 agonists like semaglutide and tirzepatide, will dominate medicine for the next 50 years. They emphasized the enduring importance of metformin, a 50-year-old drug, in managing diabetes and obesity. The panel discussed the transformative potential of these medications in addressing obesity-related health issues.
Nov 13, 2025
Five important inquiries regarding GLP-1 medications for weight loss - The Washington Post
GLP-1 medications, including semaglutide and tirzepatide, are gaining popularity for obesity treatment, with one in eight Americans having tried them. New oral options like orforglipron show promise, potentially reshaping the market. However, concerns about muscle loss and the need for further research on their anti-inflammatory effects remain. The FDA may approve oral GLP-1s soon, enhancing accessibility.
Nov 13, 2025
Mangoceuticals collaborates with Lilly and Novo Nordisk to market weight-loss medications - TradingView
Telehealth company Mangoceuticals (MGRX) announced a partnership with Eli Lilly (LLY) and Novo Nordisk (NOVO_B) to offer their popular weight-loss medications through its platform.
Nov 13, 2025
Mangoceuticals experiences a decline following Novo Nordisk and Lilly's rejection of a collaboration on obesity medications - TradingView
Shares of Mangoceuticals (MGRX), also known as MangoRx, fell 22.5% to $1.35 after a brief surge following a partnership announcement with Eli Lilly (LLY) and Novo Nordisk (NOVO_B) to sell their weight-loss drugs. Both companies later clarified that no such partnership exists. MGRX is down 25.3% year-to-date.
Nov 13, 2025
Q3 Review of Branded Pharmaceutical Stocks: Analyzing Corcept (NASDAQ:CORT) Performance
In Q3, branded pharmaceutical stocks showed resilience, with revenues surpassing estimates by 2.3%. Corcept (NASDAQ:CORT) reported $207.6 million, missing expectations, while Eli Lilly (NYSE:LLY) excelled with $17.6 billion, exceeding forecasts by 9.6%. Collegium Pharmaceutical (NASDAQ:COLL) also performed well, with a 31.4% revenue increase. Overall, the sector faces challenges from regulatory scrutiny and patent cliffs.
Nov 13, 2025
Mangoceuticals sees a surge in stock after collaborating with Lilly and Novo Nordisk to market weight-loss medications.
Shares of Mangoceuticals (MGRX), also known as MangoRx, surged 35% to $2.33 premarket after announcing partnerships with Eli Lilly (LLY) and Novo Nordisk (NOVO_B) to sell their popular weight-loss drugs. The company launched MangoRx Direct and PeachesRx Direct programs to offer these GLP-1 medications, despite a 27.3% decline in shares year-to-date.
Nov 13, 2025
Mangoceuticals collaborates with Lilly and Novo Nordisk to market weight-loss medications - Yahoo Finance
Mangoceuticals has partnered with Eli Lilly and Novo Nordisk to sell their weight-loss drugs, Zepbound and Wegovy, to self-paying patients. This collaboration follows a lawsuit from Lilly against Mangoceuticals for selling products containing tirzepatide. The partnership coincides with a White House deal to reduce drug prices, expected to drop between $149 and $350 monthly.
Nov 13, 2025
One Compelling Reason to Invest in LLY's Shares This November - The Globe and Mail
Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, has become the world's best-selling drug, generating $24.8 billion in sales. A recent deal with the Trump administration will allow Medicare to cover these GLP-1 weight-loss drugs at discounted prices, expanding access to millions. Lilly holds a 57% market share in this growing sector, projected to exceed $200 billion by 2031.
Nov 13, 2025
The international pharmaceutical and biotechnology sectors are experiencing significant changes as the patent for... approaches its expiration.
The patent for semaglutide, the key ingredient in Novo Nordisk's obesity treatment Wegovy, is set to expire next year, prompting a surge in affordable generic drug development in India and China. Novo Nordisk has preemptively reduced prices for its drug Hugo Bee in India amid competition from Eli Lilly's Maunzaro. The global obesity treatment market is expected to grow significantly, with increased access for patients.
Nov 13, 2025
NAFDAC is utilizing advanced technology and innovative approaches to combat drug counterfeiting, according to Adeyeye.
The National Agency for Food and Drug Administration and Control (NAFDAC) is utilizing modern technologies and innovative strategies to combat drug counterfeiting and unregistered products, according to Director-General Mojisola Adeyeye. This initiative aims to enhance the safety and integrity of pharmaceuticals in Nigeria.
Nov 13, 2025
How Major Pharmaceutical Companies Aim to Undermine the Cannabis Sector as We Know It
Big Pharma is strategically positioning itself for the anticipated federal rescheduling of cannabis to Schedule III, aiming to dominate the U.S. cannabis market. Companies like Pfizer, Jazz Pharmaceuticals, and AbbVie are ramping up patent filings, acquisitions, and clinical trial infrastructures to secure a competitive edge. This shift could redefine the cannabis landscape, favoring pharmaceutical control over traditional operators.
Nov 13, 2025
Exploring Trump's stance on patent regulations and a novel treatment for malaria - STAT News
Novartis has announced a potential new malaria treatment, GanLum, which cured over 99% of cases in a late-stage study. This marks the first major innovation against malaria in over 25 years, addressing the growing threat of drug resistance in sub-Saharan Africa. The new drug could complement existing artemisinin-based therapies, which are becoming less effective.
Nov 13, 2025
Akums Drugs & Pharma Plans to Allocate $24 Million for Healthcare Subsidiary in Zambia
Akums Drugs & Pharma plans to invest $24 million in its new subsidiary, Akums Healthcare (Zambia) Private Limited, to establish a manufacturing facility in Zambia. The investment, phased over three years, aims to expand operations in the growing Zambian pharmaceutical market, projected to exceed $300 million by 2030. This move enhances Akums' global presence and supports local healthcare development.
Nov 13, 2025
Cardiol Therapeutics Secures U.S. Patent Approval Valid Until 2040 | CRDL Stock Update
Cardiol Therapeutics has received a U.S. patent allowance for its heart drugs, CardiolRx™ and CRD-38, extending protection until late 2040. This patent covers treatments for various cardiac disorders, including heart failure and atherosclerosis, enhancing Cardiol's intellectual property portfolio globally. The company is advancing clinical programs for recurrent pericarditis and acute myocarditis, with upcoming data presentations planned.
Nov 13, 2025
Changes in USPTO policies could impede competition among biosimilars and affect medication prices.
The USPTO's new policies may hinder biosimilar competition and affect drug costs, critics warn. The changes could complicate patent challenges for biologic drugs, potentially delaying the entry of lower-cost alternatives and raising prices for consumers. Advocates for affordable healthcare express concern over limited access to essential treatments due to strengthened patent protections.
Nov 13, 2025
Recent changes in patent office regulations could hinder the availability of affordable medications for consumers.
The U.S. Patent and Trademark Office's new policies aim to strengthen patent protection, but critics, including some drug companies, argue they may hinder the validation of patents and limit access to lower-cost medicines. This shift could contradict the Trump administration's goals of promoting affordable healthcare options.
Nov 13, 2025
Fresenius, Sun, and Teva are among the pharmaceutical companies that have withdrawn products in the past few weeks.
Fresenius, Sun, and Teva are among the drugmakers that have recently recalled various products, including hospital drugs, potassium deficiency injections, antibiotics, and a generic medication for attention-deficit/hyperactivity disorder. These recalls have come to the attention of the FDA since the beginning of November 2025.
Nov 13, 2025
Cipla, Natco Pharma, and Hetero Labs are among the Indian companies selected to provide essential generic medications in China.
Cipla, Natco Pharma, and Hetero Labs are among Indian pharmaceutical companies selected to supply key generic drugs in China, including the diabetes medication Dapagliflozin. This marks a significant advancement for Indian firms in the Chinese market.
Nov 12, 2025
Biocon aims for regulatory clearance by FY27 for its biosimilar version of the weight loss medication Ozempic.
Biocon plans to seek regulatory approvals by FY27 for its biosimilar to the weight loss drug Ozempic. CEO Siddharth Mittal highlighted strong insulin demand in emerging markets and the company's strategy to leverage expanded manufacturing capacity in Malaysia to explore new opportunities.
Nov 12, 2025
Novo Nordisk reduces Wegovy's price by as much as 33% in India, according to a document - TradingView
Novo Nordisk has reduced the price of its weight-loss drug, Wegovy, by up to 33% in India to enhance its market position against Eli Lilly's Mounjaro. Wegovy's highest dose will now cost 16,400 rupees, down from 24,389.06 rupees. Both drugs are GLP-1 receptor agonists, with Wegovy's active ingredient being semaglutide, set to go off patent in 2026.
Nov 12, 2025
Novo Nordisk MD: India's use of obesity medication is merely the 'beginning' - India Today
Novo Nordisk plans to enhance its presence in India with Wegovy, a weight-loss injection that offers cardiovascular and kidney benefits. Following a 37% price cut, the drug's weekly cost is now Rs 2,712. Despite competition from Eli Lilly's Mounjaro, Wegovy aims to address India's obesity crisis, affecting 250 million people, and is expected to reshape the obesity treatment landscape.
Nov 12, 2025
Eli Lilly's popular weight-loss medications contribute to a significant increase in exports from Ireland.
Eli Lilly's weight-loss drugs, Mounjaro and Zepbound, have driven a significant increase in Irish exports of protein- and peptide-based hormones to the US, particularly to Indiana, where the company is headquartered. Irish exports surged by 153% to €71 billion in early 2023, with $42.3 billion linked to these hormones, reflecting strong US demand and stockpiling ahead of potential tariffs.
Nov 12, 2025
Surge in weight loss medications could safeguard Ireland's corporate tax revenue, according to regulatory agency.
A report by Ireland’s Fiscal Advisory Council highlights that the surge in pharma exports, particularly from weight-loss drugs like Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, has bolstered Ireland's corporation tax revenues. However, potential US tariffs and drug price reforms pose risks to future tax receipts, which heavily rely on large US multinationals.
Nov 12, 2025
Tahir Amin from I-MAK urges the US Congress to consider the impact of patents on medication costs | MLex
Tahir Amin, CEO of the Initiative for Medicines, Access, and Knowledge (I-MAK), is calling on lawmakers to scrutinize patent practices like evergreening and thickets that inflate drug prices. Despite criticism of I-MAK's data, Amin emphasizes the need for transparency and debate to reform patent policies and foster competition in the pharmaceutical market.
Nov 12, 2025
Sandoz anticipates the introduction of generic versions of Ozempic in Canada by the conclusion of June 2026.
Sandoz SDZ plans to launch unbranded versions of Novo Nordisk's NOVO_B diabetes drug Ozempic in Canada by mid-2024, following the expiration of the semaglutide patent. CEO Richard Saynor anticipates high demand exceeding supply for these GLP-1 medicines, while noting challenges in the regulatory landscape. Novo's patents for semaglutide will also expire in other major markets next year.
Nov 12, 2025
Pharmaceutical Company and Lexaria Extend Material Transfer Agreement
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) has extended its Material Transfer Agreement with a pharmaceutical company (PharmaCO) until April 30, 2026, to evaluate its DehydraTECH™ technology. This extension allows PharmaCO to review data from Lexaria's Australian study, with final results expected by the end of Q4 2025.
Nov 12, 2025
Exploring the Reasons Behind the Resurgence of China's Pharmaceutical Sector
In the past decade, China's pharmaceutical industry has transitioned from producing mainly active pharmaceutical ingredients (APIs) and generic drugs to becoming a leader in innovative drug development. In 2024, China approved 48 innovative drugs, ranking second globally in new drug research. Companies like Qilu Pharmaceutical are now crucial suppliers, addressing U.S. drug shortages, particularly in cancer treatments like cisplatin.
Nov 12, 2025
Amphastar Pharmaceuticals Reports Q3 Earnings for Generic Pharmaceuticals (NASDAQ: AMPH)
Amphastar Pharmaceuticals (NASDAQ: AMPH) reported Q3 revenues of $191.8 million, exceeding analysts' expectations by 4%, despite flat year-on-year growth. The company, known for complex drug formulations, saw its stock rise 12.2% post-results. The generic pharmaceutical industry remains competitive, benefiting from consistent demand for affordable medications while facing pricing pressures and regulatory challenges.
Nov 12, 2025
Chhattisgarh medical services corporation bans three medications following batch testing results.
Chhattisgarh Medical Services Corporation (CGMSC) has blacklisted three drug products for three years due to quality failures. The flagged items include Calcium with Vitamin D3 tablets and albendazole tablets from Himachal Pradesh, and Heparin sodium 1000 IU/ml injection from Gujarat. CGMSC emphasized patient safety and initiated quarantine and recall procedures while conducting further testing.
Nov 12, 2025
Novo Nordisk Aims to Introduce Ozempic in India Before Patent Expiration, Plans to Import the Drug
Novo Nordisk plans to launch its diabetes drug Ozempic in India ahead of its global patent expiry in March 2026. The drug has received CDSCO approval and will initially be imported from Denmark. The company aims to address India's significant diabetes and obesity issues, with a focus on increasing access to GLP-1 therapies.
Nov 12, 2025
Will NVO's Ozempic and Wegovy Sales Recover in 2026 Following a Lackluster Q3? - TradingView
Novo Nordisk (NVO) reported disappointing third-quarter results, with sales of its GLP-1 drugs, Ozempic and Wegovy, slowing amid competition from Eli Lilly (LLY). The company has trimmed its 2025 outlook and announced a restructuring plan to cut 9,000 jobs. NVO aims to recover by cutting drug prices and expanding indications for its therapies, while facing challenges from competitors like LLY's Mounjaro and Zepbound.
Nov 12, 2025
Expiring pharmaceutical patents create opportunities for the promotion of generic medications - Business Insurance
The expiration of patents for Zocor (simvastatin) and Zoloft (sertraline) presents a significant opportunity for insurers and pharmacy benefit managers to promote generic drug use. The FDA recently approved generics for both drugs, which are expected to boost generic dispensing rates. Insurers like WellPoint and Blue Cross Blue Shield are implementing programs to encourage the switch to generics, aiming for substantial cost savings.
Nov 12, 2025
What Impact Did Skyrizi and Rinvoq Have on AbbVie's Third Quarter Results? - TradingView
AbbVie’s immunology drugs, Rinvoq and Skyrizi, have significantly boosted the company's revenue, replacing Humira amid its generic erosion. In Q3 2025, Skyrizi sales rose 46% to $4.71 billion, while Rinvoq generated $2.18 billion, up 34%. AbbVie anticipates combined sales of over $25 billion this year, driven by strong market share gains and new indications.
Nov 12, 2025
Pfizer Secures Metsera, Trump Finalizes GLP-1 Pricing Agreement, FDA Grants Additional Priority Vouchers
Pfizer has acquired Metsera for approximately $10 billion, increasing its original bid by nearly $3 billion. Meanwhile, Novo Nordisk and Eli Lilly announced a deal to offer their GLP-1 drugs at $350 per month, significantly lower than current prices. Lilly also reported a 20% weight loss in a study of eloralintide and secured partnerships worth $1.7 billion.
Nov 11, 2025
SPDS to Conduct Training on Dissolution Science for Regulatory Officials on November 12, 2025
The Society for Pharmaceutical Dissolution Science (SPDS) will host a training program on dissolution science for regulatory officials on November 12, 2025, in Mumbai. In collaboration with the DCGI, IPC, and Maharashtra FDA, the initiative aims to enhance knowledge and compliance in pharmaceutical quality control and drug development processes.
Nov 11, 2025
Top Pharmaceutical Stocks to Watch Today - November 11th - MarketBeat
Eli Lilly, Pfizer, Novo Nordisk, AbbVie, Bristol Myers Squibb, Abbott Laboratories, and Gilead Sciences are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are noted for their significant trading volumes and diverse drug portfolios, including treatments for diabetes, cancer, and COVID-19, amidst sector-specific risks like regulatory decisions and clinical trial outcomes.
Nov 11, 2025
Trump's initiative on drug pricing overlooks the Medicare negotiation program.
President Trump has announced deals with Novo Nordisk and Eli Lilly to lower prices for Wegovy and Zepbound, while Medicare's drug price negotiation program, established under the Inflation Reduction Act, is set to release new prices for 15 drugs, including Ozempic and Wegovy, by November 30. Experts emphasize the importance of Medicare negotiations for long-term cost reductions.
Nov 11, 2025
Reasons Behind Novo Nordisk's Price Reduction for Its Weight-Loss Medication in India: 5 Essential Insights - CryptoRank
Novo Nordisk has reduced the price of its weight-loss drug Wegovy by up to 33% in India to enhance accessibility and compete with Eli Lilly's Mounjaro. The new price for the 2.4 mg dose is ₹16,400, down from ₹24,389. This strategic move comes ahead of impending generic competition and aims to capture market share in India's growing obesity treatment sector.
Nov 11, 2025
Report Indicates Significant Price Reduction for Weight-Loss Medication Wegovy in India - NDTV Profit
Novo Nordisk has reduced the price of its weight-loss drug Wegovy by up to 33% in India, with the highest dose now costing Rs 16,400. This move comes as Wegovy competes with Lilly's Mounjaro, which has seen rapid sales growth. Both drugs are GLP-1 receptor agonists, with Wegovy's active ingredient being semaglutide, set to go off patent in March 2026.
Nov 11, 2025
What is Pfizer's Outlook for the Next Three Years? - The Globe and Mail
Pfizer faces challenges as it approaches patent expirations for key drugs Ibrance, Eliquis, and Vyndaqel in 2027 and 2028. The company’s acquisition of Metsera, aimed at bolstering its drug pipeline, is now complicated by legal disputes after Metsera received a better offer. Investors are concerned about Pfizer's future, reflected in its high dividend yield of 6.9%.
Nov 11, 2025
Novo Nordisk reduces Wegovy's price by as much as 33% in India, according to a document.
Novo Nordisk has reduced the price of its weight-loss drug, Wegovy, by up to 33% in India to enhance its market position against Eli Lilly's Mounjaro. Wegovy's highest dose will now cost 16,400 rupees, down from 24,389.06 rupees. This price cut comes as both companies compete in a rapidly growing obesity treatment market projected to reach $150 billion by 2030.
Nov 11, 2025
Forecast and Size of the U.S. Pharmaceutical Market from 2025 to 2033 | Longevity - Vocal Media
The U.S. pharmaceutical market is projected to reach $979.25 billion by 2033, growing at a CAGR of 4.86%. Key drivers include an aging population, rising chronic diseases, and biotech innovations. Major companies like Pfizer Inc., AbbVie Inc., and Merck & Co. are leading this growth, with advancements in mRNA vaccines and CAR-T therapies shaping the future of healthcare.
Nov 11, 2025
Novo Nordisk partners with Emcure to expand the reach of its popular weight-loss medication in India.
Novo Nordisk India and Emcure Pharma have formed a strategic partnership to commercialize Poviztra (semaglutide injection 2.4 mg) in India, enhancing its distribution for weight loss. Emcure becomes the first Indian company with exclusive rights to Poviztra, complementing Novo Nordisk's Wegovy. This collaboration aims to improve access to obesity treatment across India, addressing significant health needs.
Nov 11, 2025
The Human Aspect of Patents: The Struggle for Essential Medications | IPWatchdog Unleashed
In a recent IPWatchdog Unleashed podcast, Sherry Knowles, founder of Knowles Intellectual Property Strategies and former Chief Patent Counsel at GlaxoSmithKline, discussed the critical role of patents in bringing life-saving drugs like Adriamycin, Cyclophosphamide, Taxol, and Herceptin to patients. She emphasized the challenges facing the patent system and the impact of generic drugs on availability, urging stronger patent protections to foster innovation in healthcare.
Nov 11, 2025
Ascelia Pharma submits a fresh patent application for Orviglance - Pharmabiz.com
Ascelia Pharma AB has filed a new patent application for its first-in-class orphan liver imaging drug, Orviglance (manganese chloride tetrahydrate), aimed at improving detection of liver lesions in patients with reduced kidney function. The patent could enhance market protection until 2046. Orviglance has received Orphan Drug Designation from the FDA, and a New Drug Application has been submitted.
Nov 11, 2025
Reviva Reveals Approval of European Patent for Brilaroxazine's Application in the ... - BioSpace
Reviva Pharmaceuticals has secured European Patent 3749324 for brilaroxazine, a drug aimed at treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). This patent complements existing protections in the U.S., China, and Japan. Brilaroxazine, which has received Orphan Drug Designation from the FDA, targets serotonin signaling disruptions linked to the disease's pathogenesis.
Nov 10, 2025
Exploring the Journey from Weight Reduction to Hair Thinning: The Quest for the Next Major Breakthrough - BioSpace
Eli Lilly's tirzepatide and Novo Nordisk's Wegovy have revolutionized weight loss treatments, while hair loss therapies are gaining traction. Pelage Pharmaceuticals and Veradermics secured $120 million and $150 million, respectively, for their innovative treatments. Pelage's PP405 targets mitochondrial metabolism, while Veradermics' VDPHL01 is an extended-release minoxidil. Both aim to address the high demand for effective hair loss solutions.
Nov 10, 2025
Five key insights for pharmaceutical marketers to consider on Monday, November 10, 2025
Eli Lilly and Novo Nordisk saw shares dip by at least 2.5% after agreeing to lower prices for their weight loss drugs in a deal with the Trump administration. Meanwhile, Gilead's breast cancer drug failed to improve progression-free survival in a late-stage study, and a patient in Intellia Therapeutics' CRISPR trial has died.
Nov 10, 2025
Violence Linked to Cough Syrup and Significant Drug Seizures of Pills and Injections Throughout India Under the NDPS Act
Law enforcement in India has intensified crackdowns on narcotics, particularly targeting codeine-based cough syrups and prescription drugs under the NDPS Act. This surge in operations has led to significant arrests and major seizures of pills and injections, addressing the rising addiction crisis.
Nov 10, 2025
U.S. Pharmaceutical Market Projected to Reach USD 907.86 Billion by 2034, According to Precedence Research
The U.S. pharmaceutical market is projected to grow from USD 520.38 billion in 2025 to USD 907.86 billion by 2034, with a CAGR of 6.34%. Key drivers include advancements in personalized medicine and AI integration. The oncology segment leads in market share, while the obesity segment is expected to grow rapidly. Major players include Johnson & Johnson, Pfizer, and AbbVie.
Nov 10, 2025
Novo Nordisk Unveils Fresh Market Approach Collaborating with Local Partners Before Patent Expiration in ...
Эксперт Владимир Лановой прокомментировал недавнее снижение курса гривны Национальным банком Украины (НБУ), отметив, что это решение не объясняется. Он считает, что украинские олигархи, являющиеся экспортерами, заинтересованы в девальвации гривны, так как это снижает их расходы в гривне и увеличивает доходы в долларах.
Nov 10, 2025
Novo Nordisk collaborates with Emcure to launch the weight loss medication semaglutide in India.
Novo Nordisk India has partnered with Emcure Pharmaceuticals to commercialize Poviztra, a second brand of the weight-loss drug Wegovy, which contains semaglutide. This collaboration aims to enhance access to obesity treatment across India, targeting over 600 million individuals affected by obesity. The partnership reflects a trend of global pharma firms collaborating with Indian companies to improve distribution and reach.
Nov 10, 2025
Ascelia Pharma Submits New Patent Application for Orviglance - BioSpace
Ascelia Pharma has filed a new patent application for its first-in-class orphan liver imaging drug, Orviglance®, aimed at enhancing market protection until 2046. CEO Magnus Corfitzen highlighted the patent's potential to boost commercial opportunities. Orviglance, an oral contrast agent for MR-imaging, has received Orphan Drug Designation from the FDA and has completed a successful clinical program.
Nov 10, 2025
Breaking Through Polymorph Limitations: Cocrystals in Generic Medications - Bioengineer.org
Recent research published in Molecular Diversity highlights the potential of co-crystals in overcoming patent barriers in generic drug development. Led by Sharma and colleagues, the study reveals that co-crystals enhance drug solubility and stability while circumventing existing polymorph patents. This innovative approach could accelerate the market entry of affordable medications, benefiting consumers and reshaping the pharmaceutical landscape.
Nov 10, 2025
Trump's agreement on obesity medication: the positives, the negatives, and the uncertainties
President Trump has negotiated a deal to lower the prices of weight-loss drugs Wegovy and Zepbound, produced by Eli Lilly and Novo Nordisk. The agreement aims to expand Medicare and Medicaid coverage for these GLP-1 treatments, although eligibility remains limited. The new prices will be significantly lower, but access and long-term fiscal impacts are still uncertain.
Nov 10, 2025
Is the agreement between the White House and pharmaceutical companies regarding GLP-1 medications a significant development? - STAT News
President Trump announced a deal with pharma companies Novo and Lilly to reduce the price of GLP-1 weight loss drugs Wegovy and Zepbound for Medicare patients. The treatments, currently priced around $1,000, will be available for approximately $250 monthly, with a $50 copay for beneficiaries. This agreement aims to enhance drug affordability and access for high-risk patients.
Nov 10, 2025
Exploring the implications of 'off-target effects' in which medications produce unintended outcomes... - GIGAZINE
A medical researcher emphasizes the importance of understanding off-target effects in drug development, which occur when drugs affect unintended targets. This knowledge can aid in drug repurposing, improve machine learning model validation, and enhance polypharmacology. EvE Bio is creating a dataset, 'EvE Bio Data,' to map off-target effects of FDA-approved drugs, available for free to researchers and for licensing to commercial entities.
Nov 10, 2025
Insurers and Employers Under Pressure to Align with Trump's Drug Agreements - Bloomberg Law News
The Trump administration's deal to lower cash prices for weight-loss drugs, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, is pressuring employers and insurers to negotiate better costs. While the deal benefits Medicare and Medicaid patients, concerns arise that drugmakers may shift costs to commercial insurance, complicating coverage for obesity medications. Innovative pricing structures may emerge as employers seek value-based deals.
Nov 10, 2025
Gene Therapy Takes a Bold Step in the Fight Against Obesity by Transforming the Body into a GLP-1 Production Hub - WebProNews
Biotech firms RenBio and Fractyl Health are pioneering gene therapy to enable the body to produce its own GLP-1, the hormone behind drugs like Ozempic and Wegovy, potentially revolutionizing obesity and diabetes treatment. Early animal studies show promise, but challenges remain regarding safety, regulatory approval, and ethical concerns. The market for GLP-1 therapies could see significant disruption as these innovations progress.
Nov 10, 2025
Increased Funding and Support from Washington: The Strategy Behind Pfizer's Victory in Metsera
Pfizer has successfully acquired Metsera for up to $10 billion, outbidding Novo Nordisk, which opted not to increase its offer. The deal, revised from an initial $7.3 billion, reflects Pfizer's strategy to re-enter the obesity drug market after previous setbacks. Metsera's board cited regulatory risks associated with Novo Nordisk's bid as a factor in their decision.
Nov 9, 2025
Three Exciting Growth Prospects for Eli Lilly Beyond GLP-1 Medications
Eli Lilly is advancing in cancer treatment through radiopharmaceuticals and has potential blockbuster Alzheimer's drug Kisunla, which could benefit from early detection methods. The company is also partnering with Nvidia to enhance drug discovery using AI. Despite a modest stock increase, Eli Lilly remains a strong growth investment with promising future opportunities.
Nov 9, 2025
Pharmaceutical advancements: The necessity for India to progress beyond generics | Policy Circle
India's pharmaceutical sector is urged to shift from low-cost generics to genuine innovation, with only $3 billion spent annually on R&D compared to $50–60 billion in the U.S. The country filed 64,487 patents in 2023, but faces challenges in clinical research, institutional collaboration, and intellectual property. A comprehensive transformation is needed to enhance India's global pharma innovation standing.
Nov 9, 2025
Stomach Organoids Transformed into Insulin-Producing Cells, Paving the Way for Diabetes Treatment
Scientists in Beijing have successfully reprogrammed human stomach organoids to secrete insulin, offering a promising new approach for treating insulin-dependent diabetes. This breakthrough could lead to innovative autologous cell-based therapies, potentially transforming diabetes management.
Nov 9, 2025
Three Exciting Expansion Prospects for Eli Lilly Beyond GLP-1 Medications | The Motley Fool
Eli Lilly (NYSE: LLY) is a strong long-term investment, driven by its successful GLP-1 drugs, Mounjaro and Zepbound. The company also has growth potential with Kisunla for Alzheimer's, radiopharmaceuticals for cancer treatment, and a partnership with Nvidia for AI-powered drug discovery. Despite recent stock fluctuations, Eli Lilly is poised for significant future growth.
